Fra side8 i rapporten om TG og Parker:
Targovax has also entered into an agreement with The Parker Institute for Cancer Immunotherapy (PICI) and the Cancer Research Institute (CRI) for a research collaboration with Targovax’s TG mutant RAS vaccine. Under the agreement, Targovax will be responsible for TG supply in a potential future trial.
Kan virke som om denne skrider fremover og blir et faktisk studie.


sterk tekst
